ArticleClinical rheumatology2026
Increased risk of cancer in patients with mixed connective tissue disease: a population-based cohort study in Korea.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWe conducted a nationwide, population-based cohort study to evaluate the risk of cancer in Korean patients with mixed connective tissue disease (MCTD) compared with the corresponding risk in the general population.
methodsUsing the Korean National Health Insurance Service data, we identified 2,094 patients with newly diagnosed MCTD between 2004 and 2020 (16,409 person-years). Standardized incidence ratios (SIRs) were calculated to compare the overall and site-specific cancer risks between patients with MCTD and the age- and sex-matched general population.
resultsThe overall risk of cancer was significantly higher in patients with MCTD than in the general population (SIR 2.61, 95% confidence interval [CI] 2.27-2.99). For site-specific cancers, both the risks of solid (SIR 2.46, 95% CI 2.12-2.84) and haematologic (SIR 6.81, 95% CI 4.36-10.13) cancers were elevated in patients with MCTD compared with the general population. Among solid cancers, increased risks were observed for several sites, including the lung, ovary, liver, pancreas, cervix, gallbladder/biliary tract, prostate, bladder, and oesophagus. Regarding haematologic cancers, multiple myeloma, myelodysplastic syndrome, and non-Hodgkin lymphoma showed increased risks. The relative cancer risk was highest in patients aged 20-39 years (SIR 4.04, 95% CI 2.90-5.48) and during the first year after MCTD diagnosis (SIR 3.77, 95% CI 2.70-5.11).
conclusionsPatients with MCTD have an increased cancer risk, particularly haematologic cancer, compared with the general population. The cancer risk was particularly elevated in younger patients and during the first year after MCTD diagnosis. Key Points • Patients with MCTD have a higher overall risk of cancer, particularly haematologic cancer. • Cancer risk is particularly elevated during the first year after MCTD diagnosis, and clinicians should not overlook the possibility of cancer in younger patients with suggestive clinical features.
Indexed as
Identifiers
42895612What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.